welcome
torontosun

torontosun

Health

Health

Eli Lilly Alzheimer’s drug Kisunla fails to get EU backing

torontosun
Summary
Nutrition label

63% Informative

Eli Lilly's drug Kisunla failed to get the backing of European regulators.

The European Medicines Agency's drug advisory committee cited a side effect known as Aria , which involves swelling and potential for bleeding in the brain.

The thumbs-down is a setback for Lilly , which is competing with Eisai Co. and Biogen in a global market for Alzheimer’s treatments.

VR Score

53

Informative language

47

Neutral language

67

Article tone

formal

Language

English

Language complexity

54

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

medium-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links

Small business owner?

Otherweb launches Autoblogger—a revolutionary way to bring more leads to any small business, using the power of AI.